CAR T-cell therapy for B-cell lymphomas: clinical trial results of available products
JC Chavez, C Bachmeier… - Therapeutic …, 2019 - journals.sagepub.com
Adoptive cellular immunotherapy with chimeric antigen receptor (CAR) T cell has changed
the treatment landscape of B-cell non-Hodgkin's lymphoma (NHL), especially for aggressive …
the treatment landscape of B-cell non-Hodgkin's lymphoma (NHL), especially for aggressive …
Graft-versus-leukemia reactions in allogeneic chimeras
HJ Kolb, C Schmid, AJ Barrett, DJ Schendel - Blood, 2004 - ashpublications.org
There is a strong graft-versus-leukemia (GVL) effect of allogeneic stem cell transplantation
(SCT) due to elimination of tumor cells by alloimmune effector lymphocytes. When leukemia …
(SCT) due to elimination of tumor cells by alloimmune effector lymphocytes. When leukemia …
Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled …
KM Ardeshna, P Smith, A Norton, BW Hancock… - The Lancet, 2003 - thelancet.com
Background Neither chemotherapy with a single-alkylating agent nor aggressive
combination chemotherapy cures advanced stage low-grade non-Hodgkin lymphomas …
combination chemotherapy cures advanced stage low-grade non-Hodgkin lymphomas …
High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized European CUP trial
HC Schouten, W Qian, S Kvaloy, A Porcellini… - Journal of clinical …, 2003 - ascopubs.org
Purpose: To determine, in a randomized clinical trial, whether high-dose therapy (HDT)
followed by autologous stem-cell transplantation is more effective than standard treatment …
followed by autologous stem-cell transplantation is more effective than standard treatment …
T lymphocytes redirected against the κ light chain of human immunoglobulin efficiently kill mature B lymphocyte-derived malignant cells
There has been interest in generating T cells expressing chimeric artificial receptors (CARs)
targeting CD19/CD20 antigens to treat B-cell lymphomas. If successful, however, this …
targeting CD19/CD20 antigens to treat B-cell lymphomas. If successful, however, this …
Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma
K Van Besien, FR Loberiza Jr, R Bajorunaite… - Blood, 2003 - ashpublications.org
In this article, we report on 904 patients undergoing transplantation for follicular lymphoma.
A total of 176 (19%) received allogeneic, 131 (14%) received purged autologous, and 597 …
A total of 176 (19%) received allogeneic, 131 (14%) received purged autologous, and 597 …
Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine …
IF Khouri, P McLaughlin, RM Saliba… - Blood, The Journal …, 2008 - ashpublications.org
Nonmyeloablative stem cell transplantation in patients with follicular lymphoma has been
designed to exploit the graft-versus-lymphoma immunity. The long-term effectiveness and …
designed to exploit the graft-versus-lymphoma immunity. The long-term effectiveness and …
An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher …
AJ Peniket, MC Ruiz de Elvira, G Taghipour… - Bone marrow …, 2003 - nature.com
The role of allogeneic bone marrow transplantation in lymphoma remains uncertain. We
have analyzed 1185 allogeneic transplants for lymphoma reported to the EBMT registry …
have analyzed 1185 allogeneic transplants for lymphoma reported to the EBMT registry …
Morbidity and mortality with nonmyeloablative compared with myeloablative conditioning before hematopoietic cell transplantation from HLA-matched related donors
R Diaconescu, CR Flowers, B Storer, ML Sorror… - Blood, 2004 - ashpublications.org
Nonmyeloablative regimens for allogeneic hematopoietic cell transplantation (HCT) have
been developed for patients ineligible for myeloablative conditioning. We compared …
been developed for patients ineligible for myeloablative conditioning. We compared …
Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the …
SP Robinson, AH Goldstone… - Blood, The Journal …, 2002 - ashpublications.org
We report the outcome of reduced-intensity allogeneic progenitor cell transplantation
(alloPCT) for 188 patients with lymphoma from the Working Party Lymphoma of the …
(alloPCT) for 188 patients with lymphoma from the Working Party Lymphoma of the …